Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

L. Malorni, P. B. Shetty, C. De Angelis, S. Hilsenbeck, M. F. Rimawi, Richard M Elledge, C. K. Osborne, S. De Placido, G. Arpino

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (p = 0.02), more proliferative (high S-phase 54 vs. 17 %, p < 0.0001), more aneuploid (64 vs. 43 %, p < 0.0001) and more likely EGFR positive (≥10 fmol/mg by radioligand-binding assay, 49 vs. 7 %, p < 0.0001). Among TN, EGFR-positive BC were larger (p = 0.0018), more proliferative (p < 0.0001), and more aneuploid, (p < 0.0001) than EGFR-negative BC. Adjuvant-treated TN patients had shorter TTFR (p = 0.0003), and OS (p = 0.0017), than ED patients. However, in untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.

Original languageEnglish (US)
Pages (from-to)795-804
Number of pages10
JournalBreast Cancer Research and Treatment
Volume136
Issue number3
DOIs
StatePublished - Dec 2012
Externally publishedYes

Fingerprint

Triple Negative Breast Neoplasms
Epidermal Growth Factor Receptor
Estrogens
Survival
Aneuploidy
Progesterone Receptors
Breast Neoplasms
Recurrence
Estrogen Receptors
Radioligand Assay
S Phase
Neoplasms

Keywords

  • Basal-like breast cancer
  • EGFR
  • Estrogen receptor
  • HER2
  • Progesterone receptor
  • Triple-negative breast cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Malorni, L., Shetty, P. B., De Angelis, C., Hilsenbeck, S., Rimawi, M. F., Elledge, R. M., ... Arpino, G. (2012). Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer Research and Treatment, 136(3), 795-804. https://doi.org/10.1007/s10549-012-2315-y

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. / Malorni, L.; Shetty, P. B.; De Angelis, C.; Hilsenbeck, S.; Rimawi, M. F.; Elledge, Richard M; Osborne, C. K.; De Placido, S.; Arpino, G.

In: Breast Cancer Research and Treatment, Vol. 136, No. 3, 12.2012, p. 795-804.

Research output: Contribution to journalArticle

Malorni, L, Shetty, PB, De Angelis, C, Hilsenbeck, S, Rimawi, MF, Elledge, RM, Osborne, CK, De Placido, S & Arpino, G 2012, 'Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up', Breast Cancer Research and Treatment, vol. 136, no. 3, pp. 795-804. https://doi.org/10.1007/s10549-012-2315-y
Malorni, L. ; Shetty, P. B. ; De Angelis, C. ; Hilsenbeck, S. ; Rimawi, M. F. ; Elledge, Richard M ; Osborne, C. K. ; De Placido, S. ; Arpino, G. / Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. In: Breast Cancer Research and Treatment. 2012 ; Vol. 136, No. 3. pp. 795-804.
@article{3e273c6315e0415fb354bb1053481e7f,
title = "Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up",
abstract = "Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (p = 0.02), more proliferative (high S-phase 54 vs. 17 {\%}, p < 0.0001), more aneuploid (64 vs. 43 {\%}, p < 0.0001) and more likely EGFR positive (≥10 fmol/mg by radioligand-binding assay, 49 vs. 7 {\%}, p < 0.0001). Among TN, EGFR-positive BC were larger (p = 0.0018), more proliferative (p < 0.0001), and more aneuploid, (p < 0.0001) than EGFR-negative BC. Adjuvant-treated TN patients had shorter TTFR (p = 0.0003), and OS (p = 0.0017), than ED patients. However, in untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.",
keywords = "Basal-like breast cancer, EGFR, Estrogen receptor, HER2, Progesterone receptor, Triple-negative breast cancer",
author = "L. Malorni and Shetty, {P. B.} and {De Angelis}, C. and S. Hilsenbeck and Rimawi, {M. F.} and Elledge, {Richard M} and Osborne, {C. K.} and {De Placido}, S. and G. Arpino",
year = "2012",
month = "12",
doi = "10.1007/s10549-012-2315-y",
language = "English (US)",
volume = "136",
pages = "795--804",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

AU - Malorni, L.

AU - Shetty, P. B.

AU - De Angelis, C.

AU - Hilsenbeck, S.

AU - Rimawi, M. F.

AU - Elledge, Richard M

AU - Osborne, C. K.

AU - De Placido, S.

AU - Arpino, G.

PY - 2012/12

Y1 - 2012/12

N2 - Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (p = 0.02), more proliferative (high S-phase 54 vs. 17 %, p < 0.0001), more aneuploid (64 vs. 43 %, p < 0.0001) and more likely EGFR positive (≥10 fmol/mg by radioligand-binding assay, 49 vs. 7 %, p < 0.0001). Among TN, EGFR-positive BC were larger (p = 0.0018), more proliferative (p < 0.0001), and more aneuploid, (p < 0.0001) than EGFR-negative BC. Adjuvant-treated TN patients had shorter TTFR (p = 0.0003), and OS (p = 0.0017), than ED patients. However, in untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.

AB - Studies on well characterized, large populations of estrogen receptor (ER)/progesterone receptor (PgR)/HER2-negative [triple-negative (TN)] breast cancer (BC) patients with long-term follow-up are lacking. In this study, we analyze clinical outcomes of TN BC and implications of epidermal growth factor receptor (EGFR) expression. Clinical and biologic features, time to first recurrence (TTFR), and overall survival (OS) were compared in 253 TN versus 1,036 ER positive, PgR positive, HER2-negative [estrogen-driven (ED)] BC. Compared to ED, TN tumors were larger (p = 0.02), more proliferative (high S-phase 54 vs. 17 %, p < 0.0001), more aneuploid (64 vs. 43 %, p < 0.0001) and more likely EGFR positive (≥10 fmol/mg by radioligand-binding assay, 49 vs. 7 %, p < 0.0001). Among TN, EGFR-positive BC were larger (p = 0.0018), more proliferative (p < 0.0001), and more aneuploid, (p < 0.0001) than EGFR-negative BC. Adjuvant-treated TN patients had shorter TTFR (p = 0.0003), and OS (p = 0.0017), than ED patients. However, in untreated patients, no differences in TTFR and OS were observed at 8 years median follow-up. Among TN patients, EGFR expression was not associated with worse outcome. TN tumors have a worse outcome in systemically treated patients but not in untreated patients. EGFR expression, does not predict for worse long-term survival.

KW - Basal-like breast cancer

KW - EGFR

KW - Estrogen receptor

KW - HER2

KW - Progesterone receptor

KW - Triple-negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=84878766469&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878766469&partnerID=8YFLogxK

U2 - 10.1007/s10549-012-2315-y

DO - 10.1007/s10549-012-2315-y

M3 - Article

C2 - 23124476

AN - SCOPUS:84878766469

VL - 136

SP - 795

EP - 804

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -